The firm's oncology unit reported 16 percent growth in Q2, with nearly all oncology medicines reporting revenue growth in the ...

NEW YORK – Estrella Immunopharma's first trial of its CD19-directed autologous T-cell therapy for non-Hodgkin's lymphoma is progressing smoothly, the company said late last week, and it has moved on ...

NEW YORK – Oak Hill Bio on Monday said it plans to go public through a merger with Research Alliance Corporation III (RACC), a special purpose acquisition company (SPAC), and raise funds to develop ...

NEW YORK – The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) on Friday recommended approval for AstraZeneca and Daiichi Sankyo's HER2-directed antibody-drug ...

It is also preclinically testing three RNA vaccines — one for cytomegalovirus-driven colorectal cancer, glioblastoma, and triple-negative breast cancer, a second for HPV-positive head and neck cancers ...

NEW YORK – The European Medicines Agency's Committee for Medicinal Products for Human Use has recommended market authorization for Gilead's Trodelvy with Merck's checkpoint inhibitor Keytruda ...

The approval was based on the Phase III SERENA-6 trial that used ctDNA testing to detect ESR1 resistance mutations and inform treatment switching.

NEW YORK – Roche is holding close details about its launch of giredestrant ahead of two US Food and Drug Administration decisions expected in the second half of the year. During a call to discuss ...

A Children's Hospital of Philadelphia team said their case study highlighted the need for increased safety monitoring.

GSK added ROS1 inhibitor to its pipeline through its $10.6 billion acquisition of Nuvalent earlier this month.

A deal with Regeneron announced in April could push the firm's revenue and income totals past $1 billion by year end.

The firm reported that two Phase III trials of Redemplo met their primary endpoints of lowering patients' triglyceride levels.